software version 12.3.0 Search Results


for windows version 10.4.3.0  (MedCalc Software Ltd)
90
MedCalc Software Ltd for windows version 10.4.3.0
For Windows Version 10.4.3.0, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/for windows version 10.4.3.0/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
for windows version 10.4.3.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
wolfram mathematica software suite version 12.3.0  (Wolfram Research)
90
Wolfram Research wolfram mathematica software suite version 12.3.0
Wolfram Mathematica Software Suite Version 12.3.0, supplied by Wolfram Research, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wolfram mathematica software suite version 12.3.0/product/Wolfram Research
Average 90 stars, based on 1 article reviews
wolfram mathematica software suite version 12.3.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
software version 12.3.0  (MedCalc Software Ltd)
90
MedCalc Software Ltd software version 12.3.0
Software Version 12.3.0, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/software version 12.3.0/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
software version 12.3.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
cox proportional hazard model medcalculator v.12.7  (MedCalc Software Ltd)
90
MedCalc Software Ltd cox proportional hazard model medcalculator v.12.7
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Cox Proportional Hazard Model Medcalculator V.12.7, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cox proportional hazard model medcalculator v.12.7/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
cox proportional hazard model medcalculator v.12.7 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
version 12.3 statistical software  (MedCalc Software Ltd)
90
MedCalc Software Ltd version 12.3 statistical software
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Version 12.3 Statistical Software, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 12.3 statistical software/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
version 12.3 statistical software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
integrator system software version 2.12.3.0  (Visiopharm AS)
90
Visiopharm AS integrator system software version 2.12.3.0
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Integrator System Software Version 2.12.3.0, supplied by Visiopharm AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/integrator system software version 2.12.3.0/product/Visiopharm AS
Average 90 stars, based on 1 article reviews
integrator system software version 2.12.3.0 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
version 123.0.0 software  (MedCalc Software Ltd)
90
MedCalc Software Ltd version 123.0.0 software
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Version 123.0.0 Software, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 123.0.0 software/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
version 123.0.0 software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
statistical package (version 12.3.0.0)  (MedCalc Software Ltd)
90
MedCalc Software Ltd statistical package (version 12.3.0.0)
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Statistical Package (Version 12.3.0.0), supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/statistical package (version 12.3.0.0)/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
statistical package (version 12.3.0.0) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
mc testing software (12.3.0 version  (Qmesys Corporation)
90
Qmesys Corporation mc testing software (12.3.0 version
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Mc Testing Software (12.3.0 Version, supplied by Qmesys Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mc testing software (12.3.0 version/product/Qmesys Corporation
Average 90 stars, based on 1 article reviews
mc testing software (12.3.0 version - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
version 12.3.0 forwindows  (MedCalc Software Ltd)
90
MedCalc Software Ltd version 12.3.0 forwindows
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Version 12.3.0 Forwindows, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/version 12.3.0 forwindows/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
version 12.3.0 forwindows - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
statistical software medcalc version 12.3.0 1993e2013  (MedCalc Software Ltd)
90
MedCalc Software Ltd statistical software medcalc version 12.3.0 1993e2013
The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from <t>Mantel-Cox</t> test are indicated. Multivariate analysis using Cox <t>proportional</t> <t>hazard</t> <t>model</t> evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.
Statistical Software Medcalc Version 12.3.0 1993e2013, supplied by MedCalc Software Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/statistical software medcalc version 12.3.0 1993e2013/product/MedCalc Software Ltd
Average 90 stars, based on 1 article reviews
statistical software medcalc version 12.3.0 1993e2013 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from Mantel-Cox test are indicated. Multivariate analysis using Cox proportional hazard model evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.

Journal: Journal for Immunotherapy of Cancer

Article Title: Differential gene expression of tumor-infiltrating CD8 + T cells in advanced versus early-stage colorectal cancer and identification of a gene signature of poor prognosis

doi: 10.1136/jitc-2020-001294

Figure Lengend Snippet: The poor prognosis CD8 + T cell gene signature is an independent prognostic indicator. The ppCD8sig was evaluated in TGCA CRC RNA-Seq dataset. Kaplan-Meier curves for disease-specific survival (A) and progression-free interval (B) were compared among patients with high (top 33%), intermediate (interm, middle 33%) or low (bottom 33%) ppCD8sig scores. The number (n) of patients in each of ppCD8sig groups and the log-rank p value from Mantel-Cox test are indicated. Multivariate analysis using Cox proportional hazard model evaluating the prognostic indication for the ppCD8sig (high, interm, low), disease stage (stages IV, III, II, (I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female) for disease-specific survival (C) and progression-free interval (D). Data shown is the HR ±95% CI and the multivariate p values are indicated. Distribution of patients with high, intermediate, or low ppCD8sig scores across disease stages (E). The presence of residual disease in patients with different ppCD8sig scores (F). χ 2 test was used to determine the association between the different ppCD8sig scores and stages or residual disease. CRC, colorectal cancer; n.s, not significant; TGCA, The Cancer Genome Atlas.

Article Snippet: Multivariate analyzes for DSS and PFI were performed using Cox proportional hazard model (MedCalculator V.12.7, https://www.medcalc.org/ ) in comparison to the ppCD8sig (high, intermediate, low), disease stage (IV, III, II, I), residual disease (yes, no), age (<55, 55–64, 65–74, >74 years of age), anatomic locations (seven different locations), and sex (male, female). χ 2 test was used to determine the association between the different ppCD8sig scores and disease stage, the presence of residual disease, age, gender or different CRC anatomical locations.

Techniques: RNA Sequencing